Abstract:Membranous nephropathy (MN) is a rare auto-immune disease where the glomerulus is targeted by circulating auto-antibodies mostly against podocyte antigens, which results in the formation of electron-dense immune complexes, activation of complement and massive proteinuria. MN is the most common cause of nephrotic syndrome in adults leading to severe thrombotic complications and kidney failure. This review is focused on the recent therapeutic and pathophysiological advances that occurred in the last two years. For a long time, we were lacking a head-to-head comparison between cyclophosphamide considered as the gold standard therapy and other medications, notably rituximab. Substantial progress has been achieved owing to three randomized controlled trials. MENTOR (Membranous Nephropathy Trial of Rituximab) and STARMEN (Sequential Therapy with Tacrolimus and Rituximab in Primary Membranous Nephropathy) conclusively established that calcineurin inhibitor-based regimens are slower to result in an immunologic response than rituximab or cyclophosphamide, achieve fewer complete clinical remissions, and are less likely to maintainremission. Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy (RI-CYCLO) suggested that competition between cyclophosphamide and rituximab remains open. Given the technological leap combining laser microdissection of glomeruli and mass spectrometry of solubilized digested proteins, four “new antigens” were discovered including NELL-1 and Semaphorin 3B in so-called primary MN, and exostosins 1 and 2 and NCAM 1 in lupus MN. NELL-1 is associated with about 8% of primary MN and is characterized by segmental immune deposits and frequent association with cancer (30%). Semaphorin 3B-associated MN usually occurs in children, often below the age of two years, where it is the main antigen, representing about 16% of non-lupus MN in childhood. Exostosins 1/2 and NCAM 1 are associated with 30% and 6% of lupus MN, respectively. Exostosins 1/2 (EXT1/2) staining is associated with a low rate of end-stage kidney disease (ESKD) even in mixed classes III/IV+V. These findings already lead to revisiting the diagnostic and therapeutic algorithms toward more personalized medicine.

Mechanisms of Primary Membranous Nephropathy

Membranous Nephropathy: Pathogenesis and Treatments

Membranous nephropathy: Mechanistic insights and therapeutic perspectives

Membranous nephropathy: Clearer pathology and mechanisms identify potential strategies for treatment

Advances in Pathogenesis of Idiopathic Membranous Nephropathy.

Advances in Membranous Nephropathy

Membranous nephropathy: Systems biology-based novel mechanism and traditional Chinese medicine therapy

Novel Biomarkers in Membranous Nephropathy

Recent Advances in Clinical Diagnosis and Pharmacotherapy Options of Membranous Nephropathy

A Novel Insight into the Role of PLA2R and THSD7A in Membranous Nephropathy

An Updated Review of Membranous Nephropathy

Immunological Pathogenesis of Membranous Nephropathy: Focus on PLA2R1 and Its Role

Perspectives in membranous nephropathy

The Genetic and Environmental Factors of Primary Membranous Nephropathy: an Overview from China

Immunology of membranous nephropathy: from animal models to humans

Autoantibodies in the Diagnosis, Monitoring, and Treatment of Membranous Nephropathy

Therapeutic targets in membranous nephropathy: plasma cells and complement

Overview of Immunological Response in Urological Membranous Nephropathy: Focus on Cytokine and Treatment Options

[Diagnosis and therapy of membranous nephropathy-2023]

The Clinicopathological Features of Patients with Membranous Nephropathy

Antiphospholipid Antibodies in Patients with Membranous Nephropathy.